Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition.
Roldán-Romero JM, Valdivia C, Santos M, Lanillos J, Maroto P, Anguera G, Calsina B, Martinez-Montes A, Monteagudo M, Mellid S, Leandro-García LJ, Montero-Conde C, Cascón A, Roncador G, Coloma J, Robledo M, Rodriguez-Antona C. Roldán-Romero JM, et al. Among authors: anguera g. Int J Cancer. 2023 Sep 15;153(6):1300-1312. doi: 10.1002/ijc.34575. Epub 2023 Jun 1. Int J Cancer. 2023. PMID: 37260183
The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer.
Marín-Aguilera M, Reig Ò, Milà-Guasch M, Font A, Domènech M, Rodríguez-Vida A, Carles J, Suárez C, Del Alba AG, Jiménez N, Victoria I, Sala-González N, Ribal MJ, López S, Etxaniz O, Anguera G, Maroto P, Fernández PL, Prat A, Mellado B. Marín-Aguilera M, et al. Among authors: anguera g. Int J Cancer. 2019 Oct 1;145(7):1970-1981. doi: 10.1002/ijc.32238. Epub 2019 Mar 23. Int J Cancer. 2019. PMID: 30807643
Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome.
Roldan-Romero JM, Santos M, Lanillos J, Caleiras E, Anguera G, Maroto P, García-Donas J, de Velasco G, Martinez-Montes ÁM, Calsina B, Monteagudo M, Letón R, Leandro-García LJ, Montero-Conde C, Cascón A, Robledo M, Rodriguez-Antona C. Roldan-Romero JM, et al. Among authors: anguera g. Mod Pathol. 2020 Dec;33(12):2580-2590. doi: 10.1038/s41379-020-0607-z. Epub 2020 Jul 2. Mod Pathol. 2020. PMID: 32616874 Free article.
Prevalence of pathogenic germline variants in patients with metastatic renal cell carcinoma.
Santos M, Lanillos J, Roldan-Romero JM, Caleiras E, Montero-Conde C, Cascón A, Climent MA, Anguera G, Hernando S, Laínez N, Robledo M, Robles L, de Velasco G, García-Donas J, Rodriguez-Antona C. Santos M, et al. Among authors: anguera g. Genet Med. 2021 Apr;23(4):698-704. doi: 10.1038/s41436-020-01062-0. Epub 2021 Jan 13. Genet Med. 2021. PMID: 33442023 Free article.
Cumulative incidences of hypogonadism, hypertension, and dyslipidaemia in patients with stage I seminoma treated with a risk-adapted strategy: a Spanish single-centre retrospective analysis.
Tapia JC, Gavira J, Anguera G, Sanchez S, Romano A, Bosma F, Molina A, Sanz-Beltran J, Martin-Lorente C, Algaba F, Maroto P. Tapia JC, et al. Among authors: anguera g. Clin Transl Oncol. 2024 Jul;26(7):1798-1803. doi: 10.1007/s12094-024-03393-9. Epub 2024 Feb 29. Clin Transl Oncol. 2024. PMID: 38421563
Treatment Patterns and Survival Outcomes Before and After Access to Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma: A Single-Center Retrospective Study From 2004 to 2021.
Tapia JC, Bosma F, Gavira J, Sanchez S, Molina MA, Sanz-Beltran J, Martin-Lorente C, Anguera G, Maroto P. Tapia JC, et al. Among authors: anguera g. Clin Genitourin Cancer. 2024 Jun;22(3):102047. doi: 10.1016/j.clgc.2024.01.019. Epub 2024 Feb 1. Clin Genitourin Cancer. 2024. PMID: 38430859
66 results